32 results

  • Adzynma (apadamtase alfa)

    (Apadamtase Alfa)
    TAKEDA PHARMACEUTICALS AMERICA, INC.
    Usage: ADZYNMA (ADAMTS13, recombinant-krhn) is indicated for prophylactic or on-demand enzyme replacement therapy in adults and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).

  • Alunbrig

    (brigatinib)
    Takeda Pharmaceuticals America, Inc.
    Usage: ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) confirmed by an FDA-approved test.

  • Carbatrol (carbamazepine)

    (carbamazepine)
    Takeda Pharmaceuticals America, Inc.
    Usage: Carbatrol is indicated as an anticonvulsant for treating partial seizures (with complex symptoms), generalized tonic-clonic seizures, and mixed seizure patterns in epilepsy. Additionally, it is used to manage pain associated with true trigeminal neuralgia and has shown benefits in glossopharyngeal neuralgia. Not intended for trivial pain relief.

  • Ceprotin (protein c concentrate human)

    (Protein C Concentrate Human)
    Takeda Pharmaceuticals America, Inc.
    Usage: CEPROTIN® is indicated for the prevention and treatment of venous thrombosis and purpura fulminans in neonates, pediatric, and adult patients with severe congenital Protein C deficiency.

  • Cinryze

    (HUMAN C1-ESTERASE INHIBITOR)
    Takeda Pharmaceuticals America, Inc.
    Usage: CINRYZE is indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years and older) with Hereditary Angioedema (HAE).

  • Cuvitru

    (Immune Globulin Subcutaneous (Human))
    Takeda Pharmaceuticals America, Inc.
    Usage: CUVITRU is indicated for replacement therapy in primary humoral immunodeficiency (PI) in patients aged two years and older. Conditions treated include common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

  • Elaprase

    (idursulfase)
    Takeda Pharmaceuticals America, Inc.
    Usage: ELAPRASE is indicated for treating Hunter syndrome (MPS II) in patients 5 years and older, improving walking capacity. In patients aged 16 months to 5 years, it reduces spleen volume, but its effects on disease symptoms are unclear. Safety and efficacy for those under 16 months remain unestablished.

  • Entyvio

    (vedolizumab)
    Takeda Pharmaceuticals America, Inc.
    Usage: ENTYVIO is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).

  • Eohilia (budesonide)

    (Budesonide)
    TAKEDA PHARMACEUTICALS AMERICA, INC.
    Usage: EOHILIA™ is indicated for 12 weeks of treatment in adults and pediatric patients aged 11 and older with eosinophilic esophagitis (EoE). It is not proven safe or effective for EoE treatment beyond 12 weeks.

  • Firazyr

    (icatibant acetate)
    Takeda Pharmaceuticals America, Inc.
    Usage: FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.